Our tech and life sciences teams provide seamless expert advice for global companies and investors in the fast-growing digital health industry. Our clients are renowned investors, from prominent early-stage funds to the largest global venture capital firms, and ambitious global digital health companies who, with our support, are revolutionizing the industry.
Through our established investor network we create transformative funding solutions for clients at all business stages, creating substantial financial foundations for growth and on-going development.
With experts in the UK, Europe, the Middle East, and Asia, together with our key partner collaborations in the US, our specialist approach in the provision of finance and capital raising, regulatory and data privacy, and IP, coupled with cross border expertise, provides the foundations for significant and sustainable global expansion for our clients. Our comprehensive awareness of the regulatory challenges facing emerging digital health companies both internally, and among ecosystem partners, is invaluable.
Supported by our data privacy and security teams, we successfully resolve personal data issues particular to digital and app-based devices and the broader regulatory challenges faced by our clients within a rapidly changing industry.
Similarly, our highly regarded IP team helps digital health companies achieve important milestones by securing, developing, and protecting valuable IP assets. This includes restructuring and executing sophisticated agreements and collaborations, partnerships and licensing agreements, and acquiring and divesting valuable businesses through strategic M&A.
Latest news & insights
EU and medicines supply issues (part one): Current measures
Marketing Authorisation Holders (MAHs) in the EU are legally required to report medicine supply shortages to the European Medicines Agency and national authorities. This article explores the central role of Marketing Authorisation Holders (MAHs) in identifying and managing medicine supply shortages in the EU as well as the role of EMA committees and working groups in coordinating responses and maintaining the Critical Medicines List to safeguard public health.
2 of 5 Insights
EU and medicines supply issues (part two): Proposals for future measures
In part two of our article on EU and medicine supply issues we explore the key proposals outlined in pharmaceutical reform and their impact on marketing authorisation holders across the region.
3 of 5 Insights
Guidance to manufacturers withdrawing a medical device from the EU market
Medical product availability and healthcare safety are becoming increasingly important talking points. This is also reflected in the EU regulations on medical devices. Although the provisions may seem straightforward their vagueness may give rise to significant doubts as to which situations they will apply to in practice.
4 of 5 Insights
Comparison of national measures to protect the supply of medicines and medical devices
Our international team has developed a practical guide that allows users to navigate different European jurisdictions, identifying medicines subject to supply restrictions, and understand manufacturers' obligations during shortages or product withdrawals.
5 of 5 Insights
Starting a telemedicine business today - how do I proceed?
